Clinical and economic consequences of pharmacogenetic-guided dosing of warfarin

TI Verhoef; T Schalekamp; Ken Redekop; A Boer; AH Maitland-van der Zee

doi:10.1586/erp.10.42

Clinical and economic consequences of pharmacogenetic-guided dosing of warfarin

TI Verhoef
, T Schalekamp
, Ken Redekop
, A Boer
, AH Maitland-van der Zee

Health Economics (HE)

External organisation

Research output: Contribution to journal › Article › Academic › peer-review

3 Citations (Scopus)

55 Downloads (Pure)

Original language	English
Pages (from-to)	375-378
Number of pages	4
Journal	Expert review of pharmacoeconomics & outcomes research
Volume	10
Issue number	4
DOIs	https://doi.org/10.1586/erp.10.42
Publication status	Published - 2010

Research programs

EMC NIHES-05-63-02 Quality

Access to Document

10.1586/erp.10.42

20100907-191.pdfFinal published version, 223 KB

http://hdl.handle.net/1765/21095

Cite this

@article{4096bc54bc5a463f8f713917014bc9f5,

title = "Clinical and economic consequences of pharmacogenetic-guided dosing of warfarin",

author = "TI Verhoef and T Schalekamp and Ken Redekop and A Boer and \{Maitland-van der Zee\}, AH",

year = "2010",

doi = "10.1586/erp.10.42",

language = "English",

volume = "10",

pages = "375--378",

journal = "Expert review of pharmacoeconomics \& outcomes research",

issn = "1473-7167",

publisher = "Taylor \& Francis Ltd (UK)",

number = "4",

}

TY - JOUR

T1 - Clinical and economic consequences of pharmacogenetic-guided dosing of warfarin

AU - Verhoef, TI

AU - Schalekamp, T

AU - Redekop, Ken

AU - Boer, A

AU - Maitland-van der Zee, AH

PY - 2010

Y1 - 2010

U2 - 10.1586/erp.10.42

DO - 10.1586/erp.10.42

M3 - Article

C2 - 20715914

SN - 1473-7167

VL - 10

SP - 375

EP - 378

JO - Expert review of pharmacoeconomics & outcomes research

JF - Expert review of pharmacoeconomics & outcomes research

IS - 4

ER -